Olema Pharmaceuticals, Inc. (NasdaqGS: OLMA)
Health Care · Biotechnology · US
$7.36
-5.88% today · -27.3% 1Y
Olema Pharmaceuticals, Inc. (NasdaqGS: OLMA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $684.23M and employs 150 people.
Over the last twelve months the share price has lost 27.3%, trading between 6.65 and 36.26.
Tweenvest scores Olema Pharmaceuticals, Inc. across four factors: quality 39/100, value 47/100. Its strongest factor is value.
OLMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $684.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.13
- Dividend yield
- —
- Beta (5Y)
- 2.01
- 52-week high
- $36.26
- 52-week low
- $6.65
- Avg volume (3M)
- —
- Shares outstanding
- 87.50M
- Employees
- 150
- Next earnings
- —
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
- ISIN
- US68062P1066
- Founded
- 2006
- Listed since
- Nov 19, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MiMedx Group, Inc.NasdaqCM: MDXG | $704.02M | $4.83 | +3.43% |
| Pharming Group N.V.ENXTAM: PHARM | $691.81M | €0.88 | -0.16% |
| Kexing Biopharm Co., Ltd.SHSE: 688136 | $689.04M | CN¥23.24 | -4.24% |
| Nuvectis Pharma, Inc.NasdaqCM: NVCT | $688.12M | $19.69 | -6.77% |
| Design Therapeutics, Inc.NasdaqGS: DSGN | $682.77M | $10.91 | -6.35% |
| Aura Biosciences, Inc.NasdaqGM: AURA | $678.23M | $6.54 | 0.00% |
| Qurient Co., Ltd.KOSDAQ: A115180 | $676.80M | ₩22,350.00 | -9.70% |
| Sunmax Biotechnology Co., Ltd.TPEX: 4728 | $674.51M | NT$396.00 | +0.38% |
Figures last refreshed Oct 11, 2026.